Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

89,554 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perioperative chemotherapy with docetaxel plus oxaliplatin and S-1 (DOS) versus oxaliplatin plus S-1 (SOX) for the treatment of locally advanced gastric or gastro-esophageal junction adenocarcinoma (MATCH): an open-label, randomized, phase 2 clinical trial.
Jiang Z, Xie Y, Zhang W, Du C, Zhong Y, Zhu Y, Jiang L, Dou L, Shao K, Sun Y, Xue Q, Tian Y, Gao S, Zhao D, Zhou A. Jiang Z, et al. Among authors: zhang w. Gastric Cancer. 2024 May;27(3):571-579. doi: 10.1007/s10120-024-01471-z. Epub 2024 Mar 8. Gastric Cancer. 2024. PMID: 38457083 Free PMC article. Clinical Trial.
A multi-center retrospective study on the efficacy and safety of regorafenib vs. regorafenib combined with PD-1 inhibitors as a second-line therapy in patients with advanced hepatocellular carcinoma.
Yan T, Huang C, Peng C, Duan X, Ji D, Duan Y, Zhang W, Zhao H, Gao K, Yang X, Zhang L, Cheng J, de Castria TB, Pocha C, Tsilimigras DI, Wu T, Su G, Li Y, Yu L, Lu Y. Yan T, et al. Among authors: zhang l, zhang w. Ann Transl Med. 2023 Jan 31;11(2):109. doi: 10.21037/atm-22-6614. Ann Transl Med. 2023. PMID: 36819518 Free PMC article.
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.
Ruan DY, Wei XL, Liu FR, Hu XC, Zhang J, Ji DM, Huang DZ, Zhao YQ, Pan HM, Liao WJ, Yang KY, Xu N, Lu XX, Chen YL, Zhang W, Zhou H, Zhao HY, Xu RH. Ruan DY, et al. Among authors: zhang w, zhang j. J Hematol Oncol. 2024 Nov 29;17(1):118. doi: 10.1186/s13045-024-01644-4. J Hematol Oncol. 2024. PMID: 39614368 Free PMC article. Clinical Trial.
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial.
Lu S, Wu L, Jian H, Cheng Y, Wang Q, Fang J, Wang Z, Hu Y, Han L, Sun M, Miao L, Ding C, Cui J, Wang K, Li B, Li X, Ye F, Liu A, Pan Y, Cang S, Zhou H, Sun X, Shen Y, Wang S, Zhang W, He Y. Lu S, et al. Among authors: zhang w. Lancet Respir Med. 2023 Jul;11(7):624-636. doi: 10.1016/S2213-2600(23)00135-2. Epub 2023 May 5. Lancet Respir Med. 2023. PMID: 37156249 Clinical Trial.
89,554 results
You have reached the last available page of results. Please see the User Guide for more information.